meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic glioblastoma (mGB) - 2nd line (L2)
head and neck cancer squamous cell cancer (HNSCC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
avelumab based treatment
avelumab alone
durvalumab based treatment
durvalumab alone
finotonlimab (SCT-I10A)
nivolumab based treatment
nivolumab alone
nivolumab plus epacadostat
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus 5FU plus platin
retifanlimab plus enoblituzumab
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
Immunostimulant
IRX-2
no study with result for this clinical condition